Dr. Rodney Breau | Faculty of Medicine

Dr. Rodney Breau, MD

Claim this profile

The Ottawa Hospital

Studies Prostate Cancer
Studies Prostatic Neoplasm
6 reported clinical trials
14 drugs studied

Area of expertise

1Prostate Cancer
Rodney Breau, MD has run 3 trials for Prostate Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage IV
2Prostatic Neoplasm
Rodney Breau, MD has run 3 trials for Prostatic Neoplasm. Some of their research focus areas include:
Stage II
Stage I
Stage IV

Affiliated Hospitals

Image of trial facility.
The Ottawa Hospital
Image of trial facility.
Ottawa Hospital Regional Cancer Centre

Clinical Trials Rodney Breau, MD is currently running

Image of trial facility.

Genomic Biomarker-Selected Therapy

for Prostate Cancer

The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib. The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
Recruiting1 award Phase 210 criteria
Image of trial facility.

Chemotherapy

for Bladder Cancer

Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it. Standard of care for UTUC would be surgery followed by chemotherapy (adjuvant chemotherapy). However, we know from studies that have looked at cancer of the lining of the bladder, which is a similar cancer in many ways, that treating people with chemotherapy before surgery (neoadjuvant chemotherapy) can lead to longer survival compared to the standard of care. There are no studies to show this in UTUC. Neoadjuvant chemotherapy is thought to help improve survival by treating any cancer that may have spread from the original tumour but that is not visible yet on scans. This study would be the first clinical trial in Canada to evaluate the use of chemotherapy before surgery in this disease setting. Since UTUC is rare, the purpose of this study is to determine if it is possible to enrol enough patients to a trial looking at the use of chemotherapy before surgery.
Recruiting2 awards Phase 3

More about Rodney Breau, MD

Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Rodney Breau, MD has experience with
  • Placebo
  • Lupron Depot
  • Whole-body FDG PET-CT
  • Metformin
  • Tranexamic Acid
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Rodney Breau, MD specialize in?
Is Rodney Breau, MD currently recruiting for clinical trials?
Are there any treatments that Rodney Breau, MD has studied deeply?
What is the best way to schedule an appointment with Rodney Breau, MD?
What is the office address of Rodney Breau, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security